日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pathway activity profiling can predict neoadjuvant endocrine therapy response in HR+ HER2- postmenopausal early stage breast cancer

通路活性分析可以预测HR+ HER2-绝经后早期乳腺癌新辅助内分泌治疗的反应

de Gruil, N; de Groot, A F; Wesseling-Rozendaal, Y; Keizer, D; Koekenbier, C S; Vermeer, S; Cohen, D; Heijns, J B; Mandigers, C M P W; van de Wouw, A J; Cloos-van Balen, M; Ropela, J A; Oosterkamp, H M; van Bekkum, M L; Houtsma, D; Biezen, E den; Liefers, G J; Linn, S C; Kroep, J R

Higher ER load is not associated with better outcome in stage 1-3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer

ER 负荷较高与 1-3 期乳腺癌患者预后良好无关:可手术乳腺癌定量 HR 分析的描述性概述

Noordhoek, I; de Groot, A F; Cohen, D; Liefers, G J; Portielje, J E A; Kroep, J R

The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival.

血液中 mMDSC 与 DC 的比值是上皮性卵巢癌生存的敏感且易于评估的独立预测因子

Santegoets S J A M, de Groot A F, Dijkgraaf E M, Simões A M Carnaz, van der Noord V E, van Ham J J, Welters M J P, Kroep J R, van der Burg S H